Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news. Vertex Pharmaceuticals announced this week that the FDA has accepted its Biologics License ...

Antibody-drug conjugates are deceptively simple in concept: an antibody selectively delivers a cytotoxic payload to cancer cells. Manufacturing them at scale is anything but simple. ADC production ...

The ISTAND program is designed to advance promising, high-impact New Approach Methodologies (NAMs) through structured FDA engagement to inform regulatory decision-making. Acceptance of Axion’s LOI ...

Salt Lake City, Utah, February 9, 2026 – Carterra Inc., the leading provider of technologies enabling high-throughput biology, today announced the launch of the Carterra Vega High-Throughput Surface ...

Even when a cancer diagnosis has cutting edge treatments available, the threat of resistance lingers. Around 90 percent of cancer-related deaths are estimated to be related to cancer drug resistance, ...

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.

Twenty years ago, drug discovery ran on a simple script of screening compounds and hoping for a hit. This exclusive ebook, ...

Over the past decade, few areas of medicine have captured both scientific and public attention as dramatically as GLP-1 (glucagon-like peptide-1)-based therapies. First developed for diabetes, GLP-1 ...

The biotechnology industry is moving past the initial excitement of artificial intelligence (AI) to confront a more complex reality: the transition from isolated digital tools to fully integrated, ...

A scientist who assumes there is one authoritative FDA AI drug development guidance document to read would be forgiven, and wrong. The reality is closer to a paper trail: a 2021 action plan that most ...

Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease (MND) in which the motor neurons are gradually lost. As these neurons deteriorate, patients experience muscle weakness, twitching, ...